Head-To-Head Survey: Proteon Therapeutics (PRTO) & Jounce Therapeutics (JNCE)

Share on StockTwits

Proteon Therapeutics (NASDAQ: JNCE) and Jounce Therapeutics (NASDAQ:JNCE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Proteon Therapeutics and Jounce Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Proteon Therapeutics 0 1 3 0 2.75
Jounce Therapeutics 0 3 3 0 2.50

Proteon Therapeutics presently has a consensus target price of $3.00, indicating a potential upside of 25.00%. Jounce Therapeutics has a consensus target price of $13.20, indicating a potential upside of 82.83%. Given Jounce Therapeutics’ higher possible upside, analysts plainly believe Jounce Therapeutics is more favorable than Proteon Therapeutics.

Volatility & Risk

Proteon Therapeutics has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Jounce Therapeutics has a beta of 5.21, suggesting that its stock price is 421% more volatile than the S&P 500.

Earnings & Valuation

This table compares Proteon Therapeutics and Jounce Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Proteon Therapeutics N/A N/A -$29.96 million ($2.13) -1.13
Jounce Therapeutics $71.64 million 3.29 -$16.44 million ($0.57) -12.67

Jounce Therapeutics has higher revenue and earnings than Proteon Therapeutics. Jounce Therapeutics is trading at a lower price-to-earnings ratio than Proteon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Proteon Therapeutics and Jounce Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Proteon Therapeutics N/A -266.77% -72.55%
Jounce Therapeutics -50.54% -23.27% -11.42%

Insider and Institutional Ownership

50.6% of Proteon Therapeutics shares are held by institutional investors. Comparatively, 84.1% of Jounce Therapeutics shares are held by institutional investors. 45.7% of Proteon Therapeutics shares are held by company insiders. Comparatively, 44.0% of Jounce Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Jounce Therapeutics beats Proteon Therapeutics on 8 of the 12 factors compared between the two stocks.

About Proteon Therapeutics

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to improve hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.

About Jounce Therapeutics

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform. The company is also developing JTX-4014, an anti-PD-1 antagonist antibody for combination therapy. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply